Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy
Until recently, ovarian clear cell carcinoma was recognized by its unique morphology and unfavorable patient outcome primarily due to tumor chemoresistance. Recently, specific molecular characteristics of ovarian clear cell carcinoma, such as PI3CA mutation, ARID1a mutation and MET amplification, ha...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Oxford University Press
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412138/ |
| id |
pubmed-4412138 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-44121382015-04-29 Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy Yamashita, Yoriko Review Articles Until recently, ovarian clear cell carcinoma was recognized by its unique morphology and unfavorable patient outcome primarily due to tumor chemoresistance. Recently, specific molecular characteristics of ovarian clear cell carcinoma, such as PI3CA mutation, ARID1a mutation and MET amplification, have been elucidated. In addition, an association between endometriosis and the tumor has also been a focus of research in recent years. The aim of this review is to discuss the specificity and importance of molecular changes and various intriguing points that are not solved until today. Finally, future aspects, including hopes for the development of novel therapies, are discussed. Oxford University Press 2015-05 2015-01-12 /pmc/articles/PMC4412138/ /pubmed/25583423 http://dx.doi.org/10.1093/jjco/hyu221 Text en © The Author 2015. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Yamashita, Yoriko |
| spellingShingle |
Yamashita, Yoriko Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy |
| author_facet |
Yamashita, Yoriko |
| author_sort |
Yamashita, Yoriko |
| title |
Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy |
| title_short |
Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy |
| title_full |
Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy |
| title_fullStr |
Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy |
| title_full_unstemmed |
Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy |
| title_sort |
ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy |
| description |
Until recently, ovarian clear cell carcinoma was recognized by its unique morphology and unfavorable patient outcome primarily due to tumor chemoresistance. Recently, specific molecular characteristics of ovarian clear cell carcinoma, such as PI3CA mutation, ARID1a mutation and MET amplification, have been elucidated. In addition, an association between endometriosis and the tumor has also been a focus of research in recent years. The aim of this review is to discuss the specificity and importance of molecular changes and various intriguing points that are not solved until today. Finally, future aspects, including hopes for the development of novel therapies, are discussed. |
| publisher |
Oxford University Press |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412138/ |
| _version_ |
1613216615025868800 |